Monday, April 25, 2011

ACE inhibitors increase, beta-blockers reduce cancer risk

According to a study published in Breast Cancer Research and Treatment, ACE angiotensin-converting enzyme inhibitors may increase the risk of cancer recurrence, but beta-blockers may reduce it. Used together, they can cumulatively reduce risk. Ace inhibitors are used for everything from reducing blood pressure, treating heart failure, preventing strokes, and moderating kidney damage. Beta-blockers treat abnormal heart rhythms, angina, high blood pressure, and migraine.

This is lab research on mice, so the effects on humans still need to be studied. If beta-blockers are effective in humans, this could lead to an effective treatment for TNBC, according to Patricia Ganz, MD, study researcher and director of cancer prevention and control research at UCLA’s Jonsson Comprehensive Cancer Center. She was interviewed for an article on the research in HemOnc Today.

And the study shows that we should evaluate all our medicines, as our drugs affects our entire bodies.

The research was based on data from the Life After Cancer Epidemiology (LACE) study of 1,779 patients diagnosed with early-stage breast cancer.

Read more about TNBC in my book, Surviving Triple-Negative Breast Cancer.Please consider a donation to Positives About Negative to keep this site going.  

This work is entirely supported by readers.  Just click on the Donate button in the right of the page.  Thank you!

Source: Ganz, Patricia, Habel, Laurel, Weltzien, Erin, Caan, Bette Cole, Steven, 'Examining the influence of beta blockers and ACE inhibitors on the risk for breast cancer recurrence: results from the LACE cohort', Breast Cancer Research and Treatment , pp. 1-8 (2011).

No comments: